Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company granted approval to import medicinal cannabis products

The company recently completed stage I of its medicinal cannabis growing facility in Queensland.
medical cannabis leaves and tablets
The products have been successful in Europe

The Hydroponics Company Ltd (ASX:THC) has received approval from the Drug Control Section of the Department of Health to import medicinal cannabis (CBD) products from its European partner, Endoca.

Endoca supplies CBD products that have been used successfully in Europe in the treatment of epilepsy and associated neurological disorders.

The Hydroponics Company will make these products available through both the National Access Cannabis (NAC) clinics that it will be establishing, as well as direct order for patients on the Special Access Scheme.

READ: The Hydroponics Company progresses cannabis growing and distribution model

The company recently completed stage I of its R&D and growing facility in Queensland.

Stage I of the development includes greenhouses for indoor cultivation and growth of medicinal cannabis.

Stage II to focus on processing of raw material

Stage II of the company’s growth plan will focus on the processing of raw material into higher value medicinal cannabis oils for use in Australia and overseas.

These products will be provided to approved Australian patients through the NAC clinics in Australia as a branded product.

Medicinal cannabis for Tourette’s Syndrome

BOL Pharma Limited, an Israeli medicinal cannabis company, recently supplied an investigational medicinal product to The Hydroponics Company in the form of a proprietary sublingual tablet.

This is for further research into the potential benefits of medicinal cannabis in Tourette’s Syndrome.

The Hydroponics Company’s subsidiary Canndeo will act on behalf of BOL to facilitate the provision of the investigational product in support of a clinical trial by Wesley Medical Research.

The trial is expected to commence in Q2 2018.

READ: The Hydroponics Company assesses Canadian entity with C$20 million a year in revenues

Join our Crypto, Blockchain and Cannabis Telegram group here
View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

pipette and petri dish
June 20 2018
As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use